<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215433</url>
  </required_header>
  <id_info>
    <org_study_id>MOREAU MedDay 2016</org_study_id>
    <nct_id>NCT03215433</nct_id>
  </id_info>
  <brief_title>Study of Biomarkers of the Response to Biotine</brief_title>
  <acronym>BIOMARBIOT</acronym>
  <official_title>Single-centre, Observational Study, Concerning Blood-lipid Biomarkers of the Response to Treatment With Biotine, Prescribed in the Context of a Nominative TAU (Temporary Authorized Use) in Patients With an Inactive Progressive Form of Multiple Sclerosis (MS).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biotine is proposed by neurologists to patients with a progressive form of Multiple sclerosis&#xD;
      (MS) in the context of a nominative temporary authorization for use (TAU) as a&#xD;
      disease-modifying treatment for their MS. A recent study showed that with this treatment,&#xD;
      more patients experienced an improvement after one year in comparison with patients given a&#xD;
      placebo.&#xD;
&#xD;
      The objective of this study is to identify blood biomarkers to determine good responders as&#xD;
      early as possible. In addition, the blood parameters studied will make it possible to better&#xD;
      understand the mechanisms of action, that have a beneficial effect on multiple sclerosis.&#xD;
&#xD;
      The management of patients will not be modified: same number of consultations (at the&#xD;
      prescription, at 3 months, at 12 months), same clinical examination, and the same number of&#xD;
      blood samples (at the prescription, at 3 months, and at 12 months).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 8, 2016</start_date>
  <completion_date type="Actual">January 23, 2019</completion_date>
  <primary_completion_date type="Actual">January 23, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>validated disability scale (EDSS)</measure>
    <time_frame>change from baseline validated disability scale at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Walking test</measure>
    <time_frame>change from baseline walking test at 3 and 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Evolution of blood lipid biomarkers</measure>
    <time_frame>change from baseline evolution of biomarkers at 3 and 12 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Biotine</condition>
  <eligibility>
    <study_pop>
      <textblock>
        25 patients with progressive (primary or secondary) MS will be encountered over time during&#xD;
        consultations at Dijon CHU. Treatment with biotine will be proposed to patients and a&#xD;
        nominative TAU will be requested.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 65 years old&#xD;
&#xD;
          -  inactive progressive form of MS according to the Lublin classification and recorded in&#xD;
             the Burgundy EDMUS database&#xD;
&#xD;
          -  Patients with health insurance cover&#xD;
&#xD;
          -  Patients who have provided written informed consent (OFSEP)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients unable to understand the information sheet&#xD;
&#xD;
          -  Patients with remittent or active progressive MS&#xD;
&#xD;
          -  Patients with a change in the disease-modifying treatment within the previous 3 months&#xD;
&#xD;
          -  Patients treated with corticosteroids in the month before inclusion&#xD;
&#xD;
          -  Impossibility to provide patients with the necessary information&#xD;
&#xD;
          -  Patients in custody&#xD;
&#xD;
          -  Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

